Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.

Szczegóły
Abstrakt

Tytuł:: Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
Autorzy:: Pittman PR; Department of Clinical Research, U. S. Army Medical Research of Infectious Diseases (USAMRIID), Fort Detrick, MD, USA. Electronic address: .
Fisher D
Quinn X
Schmader T
Barrera-Oro JG
Źródło:: Vaccine [Vaccine] 2013 Oct 17; Vol. 31 (44), pp. 5009-14. Date of Electronic Publication: 2013 Sep 08.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
MeSH Terms:: Anthrax/*immunology
Anthrax Vaccines/*immunology
Antibodies, Bacterial/*immunology
Antibodies, Neutralizing/*immunology
Antigens, Bacterial/*immunology
Bacterial Toxins/*immunology
Adult ; Anthrax/prevention & control ; Anthrax Vaccines/administration & dosage ; Antibody Formation ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunization Schedule ; Immunization, Secondary ; Immunoglobulin G/immunology ; Male ; Middle Aged ; Neutralization Tests ; Young Adult
Contributed Indexing:: Keywords: AVA; BioThrax(®) anthrax vaccine adsorbed; Human antibody response to anthrax vaccine
Substance Nomenclature:: 0 (Anthrax Vaccines)
0 (Antibodies, Bacterial)
0 (Antibodies, Neutralizing)
0 (Antigens, Bacterial)
0 (Bacterial Toxins)
0 (Biothrax)
0 (Immunoglobulin G)
0 (anthrax toxin)
Entry Date(s):: Date Created: 20130913 Date Completed: 20140428 Latest Revision: 20131015
Update Code:: 20240104
DOI:: 10.1016/j.vaccine.2013.08.086
PMID:: 24026013
: Czasopismo naukowe

Full Text Finder

We describe the Bacillus anthracis protective antigen IgG antibody response and the B. anthracis lethal toxin neutralization activity to a delayed dose of anthrax vaccine adsorbed (AVA, BioThrax(®)) using validated assays. 373 individuals received 1, 2, or 3 priming doses, 18-24 months afterward, they received a delayed dose of AVA. Overall, 23.6% of subjects showed detectable anti-PA IgG before the boost, compared to 99.2% (P<0.0001) 28 days after the boost. Geometric mean anti-PA IgG concentration (GMC) was 1.66 μg/mL before and 887.82 μg/mL after the boost (P<0.0001). The proportion of individuals with four-fold increase in GMC following the boost ranged from 93.8% to 100%. Robust anti-PA IgG levels and B. anthracis lethal toxin neutralization activity are induced when an AVA dose is delayed as long as two years. These data support continuing with the vaccination schedule when a dose is delayed as long as two years rather than restarting the series.
(Published by Elsevier Ltd.)

Informacja